About Us

    Challenge Bioproducts Co., Ltd. (CBC) is a developer & manufacturer of biochemical products since 1990, located in Touliu Industrial Park in the central region of Taiwan. CBC is committed to the R&D of innovative products as specialty biochemicals, natural animal feed additives & biofertilizers. These products are particularly designed to help reduce chemical pollution in our environment, livestock and farm produce.

   Sustainable Life & Engineering

• For a healthier and more natural lifestyle
• For an ever-growing agriculture
• For the preservation of the natural environment

CBC's Ecological Pond

Our products are sold globally, in more than 40 countries in the world!

   Main Product Categories

• Biomedical Specialty Chemicals
• Biofeed Additives
• Biofertilizers

   Corporate History

1998
- CBC's new factory and laboratory built in Touliu.

2001
- CBC was awarded a Taiwan (ROC) patent on the production technology of Genipin.
- In order to help more 3rd degree patients in the world, CBC signed Supply Agreement and Technology Transfer agreements with Mediwound Ltd. for the pineapple enzyme Bromelain SP.

2003
- CBC was awarded an USA patent on the application of Genipin on the biomedical engineering field.
- CBC was awarded an European patent on the application of Genipin on the biomedical engineering field.
- CBC was awarded a Taiwan patent on the application of Genipin on the biomedical engineering field.
- CBC was awarded a P.R.C. (Mainland China) patent on the application of Genipin on the biomedical engineering field.

2004
- Chappion Biotechnology Co., Ltd. was established to focus on the R&D and production of high-tech biomedical and health food ingredients.
- President CK Lin was awarded the 5th outstanding alumni of the Engineering School of National Tsing-Hua University (NTHU) of Taiwan.

2005
- CBC was awarded a Canadian patent on the application of Genipin on the biomedical engineering field.

2006
- CBC was awarded a Taiwan patent on the application of Genipin on oil body.

2008
- The first plant of Chappion Biotechnology Co., Ltd. was established in Touliu Industrial Park, Taiwan.
- CBC was awarded ISO 22000 & HACCP certification by Swiss Certification.

2009
- MediWound Ltd. (Israel) achieved promising Phase III trial results on its 3rd degree burn treatment product in the EU, while the US FDA Phase III trials are underway. CBC, as the sole supplier of Bromelain SP, expects the project to revolutionize treatments for 3rd degree burn patients.

2010
- Manufacturing facilities and hardware for the production of API intermediate (Bromelain SP) were upgraded, along with an upgraded quality system.

2011
- Renewal of ISO 22000 and HACCP certification by UKAS (United Kingdom Accreditation Service) via SGS.
- Challenge Bioproducts & Chappion Biotechnology facilities were audited by Teva Pharmaceuticals Europe (Global Compliance Group), and obtained EU GMP suitability declaration as a manufacturer of API intermediate.

2012
- Nexobrid receives marketing approval in Europe by EMA, and becomes "the first medical treatment for removal of eschar from severe burn wounds". It is also the first plant-derived enzymatic drug for eschar removal for burn patients.

- President CK Lin was invited to the Taiwan-Israel Biotechnology Forum with two Israeli Nobel Laureates at NTHU, Taiwan.

2017
- To this date, CBC Genipin has been used by more than 220 research institutes/universities in over 45 countries in the world, and published more than 500 peer-reviewed scientific research literatures. We look forward to the bright future of Genipin as an API.